Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Dosing of phase 1 clinical trial for taxane TPI 287 for breast cancer initiated
June 23rd, 2005
Tapestry Pharmaceuticals, Inc. (TPPH), a company developing therapies for the treatment of cancer, announced that it has begun dosing in its phase 1 clinical trial of TPI 287, a taxane Tapestry designed to overcome the resistance that may develop in patients refractory to currently available taxanes. This phase 1 trial of TPI 287 is an open label, multicenter dose-escalation trial, designed to evaluate the safety and pharmacokinetic profile of the compound in eligible patients with recurrent and/or refractory malignancies. The trial is designed to enroll approximately 48 patients. The trial is currently planned for 2 clinical sites, the Lombardi...
Source: Women's Health Weekly (2005-06-23)
|
